|
業務類別
|
Biotechnology |
|
業務概覽
|
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focusedon the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS. |
| 公司地址
| 19800 MacArthur Boulevard, Suite 250, Irvine, CA, USA, 92612 |
| 電話號碼
| +1 949 238-8090 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.eledon.com |
| 員工數量
| 33 |
| Dr. Steven N. Perrin, PhD |
President, Chief Scientific Officer, Director |
美元 455.26K |
29/04/2025 |
| Mr. Bryan E. Smith |
General Counsel, Corporate Secretary and Chief Compliance Officer |
-- |
29/04/2025 |
| Dr. David-Alexandre C. Gros, M.D. |
Director and Chief Executive Officer |
美元 582.27K |
29/04/2025 |
| Mr. Paul Sean Little |
Chief Financial Officer and Principal Accounting Officer |
美元 459.43K |
29/04/2025 |
|
|
| Mr. Keith A. Katkin |
Chairman of the Board |
29/04/2025 |
| Dr. Steven N. Perrin, PhD |
President, Chief Scientific Officer, Director |
29/04/2025 |
| Mr. James Robinson |
Independent Director |
29/04/2025 |
| Dr. Jan L. Hillson, M.D. |
Independent Director |
29/04/2025 |
| Dr. June Lee, M.D. |
Independent Director |
29/04/2025 |
| Dr. David-Alexandre C. Gros, M.D. |
Director and Chief Executive Officer |
29/04/2025 |
| Mr. John S. McBride |
Independent Director |
29/04/2025 |
| Dr. Allan Douglas Kirk, F.A.C.S.,M.D.,PhD |
Independent Director |
29/04/2025 |
|
|
|
|
